- Home
- OLMA vs TOVX Comparison
OLMA vs TOVX Comparison
Compare OLMA & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLMA | TOVX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 7.3M |
| IPO Year | 2020 | 2006 |
Fundamental Metrics
Financial Performance| Metric | OLMA | TOVX |
|---|---|---|
| Price | $25.33 | $0.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $40.50 | N/A |
| AVG Volume (30 Days) | 2.7M | ★ 9.9M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.86 | $0.17 |
| 52 Week High | $36.26 | $2.03 |
Technical Indicators
Market Signals| Indicator | OLMA | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 49.56 |
| Support Level | $25.85 | $0.18 |
| Resistance Level | $36.26 | $0.23 |
| Average True Range (ATR) | 2.37 | 0.02 |
| MACD | -1.34 | 0.00 |
| Stochastic Oscillator | 4.35 | 74.01 |
Price Performance
Historical ComparisonAbout OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.